Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Author Correction: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer.
|
31235687 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Estrogen dependence is major driver of ER + breast cancer, which is associated with PI3K mutation.
|
30076411 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
|
31104012 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These exploratory analyses of a prospective trial in luminal breast cancer suggest high CD8 infiltration is associated with unfavorable outcome and that PI3K pathway alterations might be associated with the composition of the tumor microenvironment.
|
31391067 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer cells respond better to the Rac inhibitor (EHT-1864) and the PI3K inhibitor (AZD6482) when cultured in HA-oxime versus Matrigel.
|
31322299 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusively, this study shed lights on the effect of PI3K inhibition in chemo-sensitivity of MCF-7 cells, disclosing that combination of BKM120 and ATO could be a promising therapeutic approach in BC.
|
31539632 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our findings highlight a novel role of BTF3 in modulation of ERα-dependent transcriptional activity and its potential as a predictive marker for the response to PI3K-targeted therapy in ER + breast cancer.
|
30315845 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
3-phosphoinositide dependent protein kinase-1 (PDK1), a transducer protein that functions downstream of PI3K, is responsible for the regulation of cell proliferation and migration and it also has been found to play a key role in different cancers, pancreatic and breast cancer amongst others.
|
31683659 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis.
|
30540926 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, resistance to PI3K inhibitors in breast cancer has emerged, which is due to the enhanced β-catenin nuclear accumulation.
|
31124219 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
SAR studies demonstrated amide substituted (Z)-β-enaminones as precise PI3K inhibitors to treat breast cancer.
|
30515835 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the safety and identify the recommended phase 2 dose of the PARP inhibitor olaparib in combination with the PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast cancer.
|
30880072 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study shed new light on the tumorigenesis induced by hyper-activated PI3K and might provide new clues for the prevention and therapy of breast cancer.
|
30671946 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteoglycin (OGN) Inhibits Cell Proliferation and Invasiveness in Breast Cancer via PI3K/Akt/mTOR Signaling Pathway.
|
31824171 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI3K/AKT/mTOR is one of the most commonly identified oncogenic-driver pathways in breast cancer.
|
31320990 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have previously reported that the PI3K pathway regulates estrogen receptor (ER)-dependent transcription in breast cancer through the phosphorylation of the lysine methyltransferase KMT2D by AKT.
|
30943409 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1α) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells.
|
30930461 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, our data suggest that combined targeting of MET and PI3K could be a potential clinical strategy for breast cancer patients, where phosphorylated MET and <i>PIK3CA</i> mutation status would be biomarkers for selecting patients who are most likely to derive benefit from these cotargeted therapy.
|
30518672 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human adipose‑derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial‑mesenchymal transition by cross interacting with the TGF‑β/Smad and PI3K/AKT signaling pathways.
|
30483746 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Alpelisib (Piqray™)-an orally available phosphatidylinositol 3-kinase (PI3K) inhibitor with specific activity against PI3K alpha (PI3Kα)-is being developed by Novartis for the treatment of breast cancer.
|
31256368 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, DT-13 decreased PLOD2 expression through modulating JAK/STAT3 and PI3K/AKT signaling pathways directly or indirectly in the adipocyte-breast cancer microenvironment.
|
31005809 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<sup>11</sup>C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging.
|
31787861 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our study highlighted the complex regulation of the PI3K/AKT pathway in BC and its differences in BC patients with and without lymph node involvement.
|
31781306 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations of the PIK3CA gene are found in approximately 25% of breast carcinomas and are reported as activators of the PI3K/AKT/mTOR pathway.
|
30426328 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, we identified PIK3CB as a direct molecular interactor of miR-1287-5p and a novel prognostic factor in BC.
|
30709367 |
2019 |